Document Detail

Tetracycline-induced expression of an anti-c-Myb single-chain antibody and its inhibitory effect on proliferation of the human leukemia cell line K562.
MedLine Citation:
PMID:  10678368     Owner:  NLM     Status:  MEDLINE    
Ablation of c-Myb function might be an effective approach for the therapy of chronic myelogenous leukemia or other c-myb-dependent malignancies. To this end, we have previously used an intracellular anti-c-Myb single-chain antibody (sFv) to achieve the functional knockout of the c-Myb oncoprotein. In this study, we have employed a tetracycline-inducible system to control the expression of the sFv. A nuclear-localizing form of an anti-c-Myb sFv was cloned into a tet-regulated plasmid vector. Using a transient expression system in COS-1 cells, we observed that doxycycline (Dox) induced expression of the sFv in a dose-dependent manner, and that the sFv was localized mainly in the nucleus. The Dox-induced anti-c-Myb sFv also inhibited the transactivating activity of c-Myb in a dose-dependent manner. We subsequently confirmed the Dox-induced expression of the sFv in the leukemia cell line K562. Proliferation of the target leukemia cells was also inhibited. These results suggest that the anti-c-Myb sFv may represent a viable method for gene therapy of c-myb-dependent hematopoietic malignancies.
K Kasono; Y Heike; J Xiang; A Pich?; H G Kim; M Kim; M Hagiwara; M Nawrath; K Moelling; D T Curiel
Related Documents :
24567178 - The inhibitory effect of a new scfv/tp protein as sirna delivery system to target hwapl...
23104178 - Increased prlz-mediated androgen receptor transactivation promotes prostate cancer grow...
21084838 - Combination of the somatic cell nuclear transfer method and rnai technology for the pro...
1522128 - Regulation of cell proliferation: late down-regulation of c-myb preceding myelo-monocyt...
23825128 - Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.
17171648 - Induction of abnormal nuclear shapes in two distinct modes by overexpression of serine/...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer gene therapy     Volume:  7     ISSN:  0929-1903     ISO Abbreviation:  Cancer Gene Ther.     Publication Date:  2000 Jan 
Date Detail:
Created Date:  2000-02-29     Completed Date:  2000-02-29     Revised Date:  2010-02-25    
Medline Journal Info:
Nlm Unique ID:  9432230     Medline TA:  Cancer Gene Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  151-9     Citation Subset:  IM    
Gene Therapy Program, University of Alabama, Birmingham 35294, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies / genetics,  immunology*,  pharmacology
COS Cells
Cell Division / drug effects
Doxycycline / pharmacology
Gene Expression Regulation / drug effects
Gene Therapy
K562 Cells
Leukemia / immunology,  pathology,  therapy*
Proto-Oncogene Proteins c-myb / genetics,  immunology*
Recombinant Proteins / genetics,  immunology
Grant Support
5P30-CA13148-25/CA/NCI NIH HHS; R01 CA68245/CA/NCI NIH HHS; R01 CA72532/CA/NCI NIH HHS
Reg. No./Substance:
0/Antibodies; 0/Proto-Oncogene Proteins c-myb; 0/Recombinant Proteins; 564-25-0/Doxycycline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immunogene therapy against mouse leukemia using B7 molecules.
Next Document:  The aortic valve blood supply.